Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus

Wiener Klinische Wochenschrift

Volumn 117, Issue 17, 2005, Pages 593-598

  Lechleitner, Monika ^a,e   Roden, Michael ^b   Haehling, Eva ^c   Mueller, Markus ^d  

^a University Hospital for Internal Medicine   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c Sanofi Aventis   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Insulin glargine; Oral antidiabetic drugs; Pharmacoeconomy; Treatment costs; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; INSULIN GLARGINE;

ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARAMETER; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AUSTRIA; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 26444537458     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0429-5     Document Type: Article

References (18)

1. Initiative Arznei & Vernunft (2004) Vernünftiger Umgang mit Medikamenten. Typ 2 Diabetes. Oktober 2004, 1. Edition, S 6-17
2. Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft (DDG) (2002) Diabetes und Stoffwechsel 11 [Suppl 2]: 6-9
3. Kautzky Willer A, Lechleitner M, Pieber TR, Prager R, Roden M (2004) Therapy with insulin. Acta Med Austriaca 31: 164-165
4. Keller U (2004) Future perspectives in the treatment of type 2 diabetes. Wien Klin Wochenschr 116: 213-214
5. Stingl H, Roden M (2004) Future target in the treatment of type 2 diabetes. Wien Klin Wochenschr 116: 217-229
6. Schernthaner G (2003) Progress in the prevention of type 2 diabetes. Wien Klin Wochenschr 115: 745-757
7. Koivisto V, Tuominen J, Ebeling P (1999) Lispro Mix 25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22: 459-462
8. International Medical Statistics (IMS) (2003), Austria
9. Rosenstock J, Owens DR (2004) Basal Insulin therapy in type 2 diabetes mellitus, part one. Insulin glargine. Aesculapium Limited, London
10. Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ (2003) Insulin glargine. An updated review of its use in the management of diabetes mellitus. Drugs 63: 1743-1778
11. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
12. Janka HU, Schneider K, Schweitzer MA (2003) Basal supported oral therapy (BOT) in everyday practice. Diabetes Metab 29: Abstract 2206
13. Klinge A, Schneider K, Schweitzer MA (2003) Treatment of patients with type 2 diabetes with insulin glargine in everyday practice. Diabetes Metab 29: Abstract 2208
14. Haak T, Schreiber SA, Schneider K, Schweitzer MA (2004) Insulin glargine in type 2 diabetes: an observational study of everyday practice. Diabetologia 47: Abstract 739
15. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H (2005) Comparison of basal insulin added to oral agents versus twice-daily pre-mixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28: 254-259
16. Rosenstock J, Schwarz SL, Clark CM, Park GD, Donely DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24: 631-636
17. Riddle MC, Rosenstock J, Gerich, J (2003) The Treat-To-Target Trial. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-3086
18. Fritsche A, Schweitzer MA, Häring HU (2003) Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 138: 952-959